International Finance Facility for Immunisation issues inaugural bonds
International Finance Facility for Immunisation issues inaugural bonds
7 November 2006
Efforts to immunise children received a large boost as the IFFIm issued its inaugural bonds today. The bonds are rated AAA/Aaa/AAA.
Proceeds will be used to scale up GAVI Alliance, boost vaccine use and improve health systems to save the lives of millions of the poorest children
London, 7, November 2006 - Efforts to immunise children in the poorest countries of the world received a large boost as the International Finance Facility for Immunisation (IFFIm) issued its inaugural bonds today. The bonds are rated AAA/Aaa/AAA.
IFFIm is a new international development institution designed to accelerate the availability of funds to be used for health and immunisation programmes through the GAVI Alliance (GAVI) in 70 of the poorest countries around the world.
GAVI's success in the past five years has led six European nations: the United Kingdom, France, Italy, Norway, Spain and Sweden to make legally-binding commitments to IFFIm. Using those commitments, IFFIm anticipates raising US$4 billion over the next ten years in the international capital markets to support GAVI's health and immunisation programmes in developing countries, helping to save as many as 10 million lives.
By investing the majority of IFFIm resources up front-"frontloading"-this innovative funding institution will significantly increase the flow of aid to ensure reliable and predictable funding for immunisation programmes and health systems. The new funds will enable the GAVI Alliance to build on its successes and immunise more than 500 million children against vaccine preventable diseases before 2015.
In announcing the issuance, Gordon Brown, the Chancellor of the Exchequer said: "Millions of people campaigned to Make Poverty History last year, and now we can say to them all: we are delivering on the promises we made, your hopes are becoming a reality, and millions of young children's lives will be saved as a result."
"IFFIm represents a unique approach to financing for development. This is the first time that bonds are issued to finance a specific objective related to health and immunisation. The creation of IFFIm provides investors with an opportunity to participate in the scaling up of a highly successful public-private collaboration that is focused on saving and improving the lives of the world's youngest and most vulnerable citizens," said Alan Gillespie, Chair of IFFIm.
"In addition we are being given the opportunity to demonstrate a new way of funding international development, addressing the seemingly intractable problems of poor nations with a tried and true financing model from the capital markets," he added.
GAVI has demonstrated that the effectiveness of development assistance depends on making the funds targeted and in building flexibility into the process.
"Since its inception, GAVI and its partners have helped to save more than 1.7 million lives," said GAVI Alliance Executive Secretary, Julian Lob-Levyt. I must recognize the extraordinary commitment of the donor countries and partners who have enabled this progress and who are supporting IFFIm."
The job is far from over, though: more than 27 million children still go without immunisation every year. As a result, illnesses from preventable diseases in developing countries are nine times higher than in the richest countries.
"Even with IFFIm resources, there is still a large funding shortfall of US$ 11-15 billion over the next ten years to achieve 90% immunisation coverage in GAVI partner countries. If we could fund this shortfall, we could save an additional ten million lives over the next decade," Lob-Levyt added.
"The launch of the IFFIm is an exciting and important step. Every bond sold will make it possible to immunise more children and save more lives," said Bill Gates, co-chair of the Bill & Melinda Gates Foundation, which has pledged $1.5 billion to GAVI. "I congratulate the U.K., France, Italy, Norway, Spain, and Sweden for backing this initiative and Gordon Brown for taking IFFIm from idea to reality."
The proceeds from the first bonds will provide an immediate funding boost to GAVI's immunisation programmes. More specifically, the funds will be used to:
- Support New Vaccines
Eligible countries will be able to procure under-used and newly licensed vaccines to combat the diseases that cause a significant proportion of child mortality. - Strengthen Immunisation Services
Scaling up coverage of immunisation in the poorest countries will require substantial investments in the health systems that deliver vaccines. Countries will be able to use IFFIm's resources to alleviate these system-wide barriers and potentially lead to a more comprehensive provision of health services. - Fund Measles and Tetanus Campaigns
To drive mortality down quickly, supplemental immunisation activities will be funded in the countries where the need is greatest, such as mass campaigns for immunisation against measles and tetanus. These campaigns will be designed and executed with the additional goal of strengthening routine health and immunisation services. - Create a Polio Vaccine Stockpile
Once the world is declared to be polio-free, a stockpile of oral polio vaccine will be required to serve as an "insurance policy" against any future recurrence or outbreak. GAVI will provide the funding needed to ensure that adequate supplies of the vaccine are available.
About the GAVI Alliance
The GAVI Alliance is a public-private partnership that aims to immunise children and strengthen health systems in the world's poorest countries. It brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, NGOs, the Bill & Melinda Gates Foundation and private philanthropists. GAVI provides vaccines against diphtheria, tetanus, pertussis combined with haemophilus influenzae type b and hepatitis B as so-called pentavalent (five antigens in one vaccine) as well as vaccines against measles, yellow fever, pneumococcal diseases (pneumonia and meningitis) and rotavirus (diarrhoea).
About IFFIm
International Finance Facility for Immunisation Company (IFFIm) is a multilateral development institution created to accelerate the availability of predictable, long-term funds for health and immunisation programmes through the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunisation) in 70 of the poorest countries around the world. IFFIm was created as a development financing tool to help the international community achieve the Millennium Development Goals. IFFIm's financial base consists of legally binding grants payments from its sovereign sponsors (France, Italy, Norway, South Africa, Spain, Sweden and the UK), on the basis of which IFFIm's is rated AAA/Aaa/AAA (Fitch/Moody's/S&P). The World Bank is the Treasury Manager for IFFIm. IFFIm was established as a charity with the Charity Commission for England and Wales and is registered in England and Wales as a company limited by guarantee with number 5857343 and as a charity with number 1115413.
About the World Bank
The World Bank is a global development cooperative owned by 187 member countries. Its purpose is to help its members achieve equitable and sustainable economic growth in their national economies and to find effective solutions to pressing regional and global problems in economic development and environmental sustainability. The goal is to help overcome poverty and improve standards of living for people worldwide. The International Bank for Reconstruction and Development (IBRD), rated Aaa/AAA (Moody's/S&P), is the oldest and largest entity in the World Bank Group and provides funding, risk management tools and credit enhancement to sovereigns. To fund this activity, IBRD has been issuing debt securities in the international capital markets for 60 years. The World Bank is also the Treasury Manager for IFFIm. In that capacity, the World Bank, as IFFIm's agent, manages IFFIm's finances according to prudent policies and standards. This includes IFFIm's funding strategy and its implementation in the capital markets, rating agency and investor outreach, hedging transactions and investment management. The World Bank also coordinates with IFFIm's donors and manages their pledges and payments as well as IFFIm's disbursements for immunisation and health programmes through the GAVI Alliance.
This press release is not an offer for sale of Notes of the International Finance Facility for Immunisation Company ("IFFIm"), in the United States. The Notes are not being registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States or to US persons except pursuant to an applicable exemption from such registration. Any offering of the Notes will be made only by means of a prospectus containing detailed information regarding IFFIm and its management, including financial statements. Such prospectus will be made available through IFFIm. This press release does not constitute an offer for sale of the securities described. The offering and sale of the securities described in this document are subject to restrictions under the laws of several countries. Securities may not be offered or sold except in compliance with all such laws.
[Français] [Italiano] [Español] [Deutsche] [Nederlands] [Norsk] [Swedish]
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024